Pantoprazol Aurovitas (Pantoprazole)

Pantoprazol Aurovitas is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining.
• Erosive esophagitis: heals erosions and reduces further damage.
• Peptic ulcer disease: supports ulcer healing and prevents recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells in the stomach. By binding irreversibly to this pump, it blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity and providing an environment conducive to mucosal healing.

Pantoprazol Aurovitas may cause a range of adverse reactions. Most are mild and resolve after discontinuation.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: loose stools, often transient.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent diarrhoea with abdominal cramping.
• Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.
• Fractures of the hip, wrist or spine: associated with long‑term use.
• Acute interstitial nephritis: kidney inflammation presenting with fever and flank pain.
• Liver enzyme elevation: increased ALT/AST detected on blood tests.

Before using Pantoprazol Aurovitas, consider the following safety measures:

• Assess patient’s renal function: adjust use in severe renal impairment.
• Review the history of allergies: avoid if known hypersensitivity to pantoprazole or other PPIs.
• Monitor long‑term use: evaluate need for continued therapy after 8‑12 weeks.
• Caution in pregnancy: discuss risk vs benefit with the prescriber.
• Avoid concomitant use with certain medications that may reduce efficacy.
• Store at below 25°C: keep in the original pack, protect from moisture.

Pantoprazol Aurovitas can interact with several medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid)

• Antifungal agents (e.g., itraconazole, ketoconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors ( HIV   ).

Moderate  "). -  . - . - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ". - ",